ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 684

Evaluation of Patient Acceptable Symptom State in Patients with Axial Spondylarthritis; Similar Thresholds for Radiographic and Non-Radiographic Subgroups

Pinar Cetin1, Gercek Can1, Gokce Kenar1, Handan Yarkan1, Berrin Zengin1, Ismail Sari1, Merih Birlik1, Fatos Onen1 and Nurullah Akkoc2, 1Rheumatology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey, 2Department of Rheumatology, Dokuz Eylul University, Faculty of Medicine, Izmir, Turkey

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Spondylarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster I: Clinical Aspects and Assessments

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: The Patient Acceptable Symptom State (PASS), a single-question outcome, has been defined as an absolute level of patient well-being. A few studies have assessed PASS in patients with ankylosing spondylitis (AS), but it is not known whether the results of those studies apply also to the group of non-radiographic (nr) axial spondylarthritis (axSpA). The objective of this study is to estimate the PASS values for disease activity and several patient reported outcomes both in the whole group of axSpA and in the two subgroups of AxSpA.

Methods: This single-center cross-sectional analysis included patients fulfilling the ASAS criteria for axSpA, who have been registered in our local database. All patients responded to the global yes/no question for PASS. A variety of other outcome measures in regard with global scales, disease activity, functional status, health status and quality of life were collected at the same time. The thresholds at which patients rated themselves in PASS for disease activity (BASDAI and ASDAS) and for each of the assessed patient self-reported outcome measures were estimated using the 75th centile (25th centile for SF 36)estimation and receiver operating characteristic (ROC) analyses in the whole group, as well as in each subgroup of axSpA. Contributors which can affect PASS were evaluated with logistic regression analysis.

Results: The analysis was based on 356 axSpA patients (261 AS, 95 nr-axSpA) with a mean age of 42.2±12.0 years and mean disease duration of 14.7±10.8 years. Of the patients with axSpA, 271 (%76.1) considered themselves in PASS (76.6% in AS, 74.7% in nr-axSpA). PASS thresholds for disease activity and all other assessed outcome measures were shown in table and there were not significant difference between AS and nr-axSpA group. PASS cut-off points for BASDAI, BASFI and HAQ identified by the 75th percentile method were slightly higher than those determined by the ROC analysis, but similar for the rest of the outcome measures. The patients with an acceptable status had significantly lower mean disease activity scores and good results with the all outcome measures. PASS had no relationship with age, sex, disease duration and education (years) in logistic regression analysis. Of the axSpA patients with BASDAI (≥4), 61.4% and those with ASDAS (>3.5), 50% rated themselves in PASS, whereas 5.5% of the patients with a BASDAI score <2, and 4.5% of those with ASDAS <1.2 were not in PASS.

Conclusion: PASS thresholds for disease activity and outcome measures were similar to the figures previously reported in some studies with no apparent difference between patients with AS and nr-axSpA. However, more than half the Turkish axSpA patients considered themselves in PASS, which needs to be evaluated in further studies.

Table. Patient Acceptable Symptom State (PASS) cut-off points for disease activity and health status measures in all patients.

Parameter

 

PASS + 75th

Percentile  threshold*

ROC cut off

Area under the curve

Sensitivity/

Specificity

Disease activity

                   BASDAI  (0-100mm)

 

46.0

 

39.5

 

0.74

 

68/65

                    ASDAS

3.1

3.0

0.74

72/68

Functional measures

                    BASFI  (0-100mm)

40.0

35.5

                            0.72

69/64

                    HAQ-S

0.9

0.79

0.72

67/64

Global scales

          Pain  VAS  (0-100mm)

51.0

49.5

0.75

69/69

          Global  VAS (0-100mm)

56.8

47.5

0.77

65/73

SF 36

                    PCS

36.0

38.5

0.73

67/69

                  MCS

41.0

43.5

0.71

67/63

Quality of life

                    ASqol

8.0

6.5

0.71

68/63

                   EQ 5D

0.84

0.71

0.72

66/64


Disclosure: P. Cetin, None; G. Can, None; G. Kenar, None; H. Yarkan, None; B. Zengin, None; I. Sari, None; M. Birlik, None; F. Onen, None; N. Akkoc, None.

To cite this abstract in AMA style:

Cetin P, Can G, Kenar G, Yarkan H, Zengin B, Sari I, Birlik M, Onen F, Akkoc N. Evaluation of Patient Acceptable Symptom State in Patients with Axial Spondylarthritis; Similar Thresholds for Radiographic and Non-Radiographic Subgroups [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/evaluation-of-patient-acceptable-symptom-state-in-patients-with-axial-spondylarthritis-similar-thresholds-for-radiographic-and-non-radiographic-subgroups/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evaluation-of-patient-acceptable-symptom-state-in-patients-with-axial-spondylarthritis-similar-thresholds-for-radiographic-and-non-radiographic-subgroups/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology